Celldex axes two more programs to cut costs following glembatumumab failure; Ziopharm stock slides on halted brain cancer trial
→ New Jersey-based biotech Celldex $CLDX is cutting two programs from its pipeline, hoarding resources after the failure of its lead breast cancer drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
